The overall long term goal of this Imaging Core is to identify structural, perfusion, and metabolic changes in the brain that predict future cognitive decline and conversion to dementia. The overall approach will be to initially study healthy elders ands age/gender matched patients with well-characterized dementia associated with Alzheimer's disease and Frontotemporal dementia using a newly acquired 4 Tesla Bruker/Siemens MRI/MRS scanner, which will be optimized for investigation of neurodegenerative disease. These initial studies will provide imaging characteristics of established dementia. We will also study a group of subjects with MCl-Peterson criteria. In subsequent years we will study increasing numbers of subjects with MCI subtypes and MCl-Peterson who likely represent early stages of AD and FTD and who are expected to ultimately convert to dementia. All subjects will be recruited and evaluated by the Clinical Core.
Alzheimer's disease affects millions of Americans, and the incidence and prevalence are growing as people get older. MRI imaging provides unique information concerning the changes in the brain which occur in demented subjects, as well as in the early stages of the disease. Imaging also helps identify other processes which lead to cognitive impairment. Thus, state of the art imaging is a critical aspect of this ADRC.
| Orr, Anna G; Lo, Iris; Schumacher, Heike et al. (2018) Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis 110:29-36 |
| Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064 |
| Watson, Christa L; Possin, Katherine; Allen, I Elaine et al. (2018) Visuospatial Functioning in the Primary Progressive Aphasias. J Int Neuropsychol Soc 24:259-268 |
| Casaletto, K B; Elahi, F M; Fitch, R et al. (2018) A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? Cytokine 111:481-489 |
| Tan, Chin Hong; Fan, Chun Chieh; Mormino, Elizabeth C et al. (2018) Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathol 135:85-93 |
| Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393 |
| Sturm, Virginia E; Brown, Jesse A; Hua, Alice Y et al. (2018) Network Architecture Underlying Basal Autonomic Outflow: Evidence from Frontotemporal Dementia. J Neurosci 38:8943-8955 |
| Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306 |
| Bonham, Luke W; Geier, Ethan G; Steele, Natasha Z R et al. (2018) Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. Front Neurosci 12:476 |
| Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858 |
Showing the most recent 10 out of 590 publications
